INS and type 2 diabetes mellitus: Notably, XBL treatment led to a significant reduction in fasting blood glucose and HOMA-IR levels, alongside increased insulin secretion, indicative of improved β-cell function and enhanced peripheral insulin sensitivity—both central to T2DM pathogenesis [22].